SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
NOVATO, Calif., Feb. 09, 2016 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company’s Chief Financial Officer, will be presenting at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:00am ET at the Waldorf Astoria in New York, NY.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
